Drug Approval | December 18, 2023
Zydus receives final approval from the USFDA for Lacosamide Tablets
Lacosamide is indicated to treat partial-onset seizures
Lacosamide is indicated to treat partial-onset seizures
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Expands patient reach to remotest towns by furthering investment in GoApptiv
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
The product will be manufactured at Lupin's Pithampur facility in India
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Subscribe To Our Newsletter & Stay Updated
